EDUCATING LEADERS IN PHARMACY AND PHARMACEUTICAL SCIENCES SINCE 1886
Funded Projects
Based on current funded research
Updated May 5, 2025
Data provided by University at Buffalo Sponsored Projects Services
Horizontal scroll at bottom of table
| Award Principal Investigator | Award Name | Award Type | Sponsor Name | Award Start Date | Award End Date | Total Cost |
|---|---|---|---|---|---|---|
| Balthasar, Dr. Joseph | UB-Abceutics SRA | Nonfederal | Abceutics | 05-Mar-24 | 05-Mar-29 | 150,000.00 |
| Balthasar, Dr. Joseph | Center for Protein Therapeutics | Nonfederal | Multiple Sponsors | 01-Sep-17 | 31-Aug-25 | 13,124,501.70 |
| Balthasar, Dr. Joseph | Pharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumors | Federal | National Cancer Institute | 01-Jun-20 | 31-May-25 | 1,781,807.00 |
| Balthasar, Dr. Joseph | Enhancement of ADC selectivity by inverse targeting: Mechanistic studies and optimization | Federal | National Cancer Institute | 01-Jun-21 | 31-May-26 | 1,791,526.00 |
| Balthasar, Dr. Joseph | Pharmacokinetic / Pharmacodynamic Optimization of ADC Therapy for Acute Myeloid Leukemia | Federal | National Cancer Institute | 01-Jan-23 | 31-Jan-28 | 2,500,629.00 |
| Balthasar, Dr. Joseph | Improving antibody distribution with transient antigen binding inhibition | Nonfederal | Empire Discovery Institute | 08-Dec-22 | 30-Jun-25 | 180,000.00 |
| Balu-Iyer, Dr. Sathy V. | Lipid mediated oral tolerance | Federal | National Institute of Allergy & Infectious Disease | 16-Jun-22 | 31-May-27 | 2,367,515.06 |
| Balu-Iyer, Dr. Sathy V. | Development of tolerogenic Factor VIII as immunotherapy to prevent inhibitor development in Hemophilia A | Federal | National Heart Lung and Blood Institute | 27-Mar-23 | 28-Feb-26 | 1,121,169.00 |
| Bednarczyk, Dr. Edward M. | Overdose Data to Action State (OD2A)2024-2025 | Federal Flow Through | Health Research Inc | 01-Sep-24 | 31-Aug-25 | 115,000.00 |
| Bednarczyk, Dr. Edward M. | C19: Chronic Disease Medication Utilization and the Novel Coronavirus Disease 2019 (COVID-19) Infection | Nonfederal | American College of Clinical Pharmacy | 01-Jan-21 | 31-Dec-25 | 600.00 |
| Bies, Dr. Robert R. | A Pilot Study for measuring drug concentration in the Female Reproductive Tract | Nonfedearl | Magee-Womens Research Institute and Foundation | 01-Oct-24 | 30-Sep-26 | 144,835.00 |
| Bies, Dr. Robert R. | CHIPP-PrEP: Cabotegravir-Hormone Interrogation of Pharmacokinetics/Pharmacodynamics for HIV Prevention in Cisgender and Transgender Persons | Federal Flow Through | Johns Hopkins University | 01-Aug-24 | 31-Jul-29 | 371,827.00 |
| Bies, Dr. Robert R. | Evaluation of safety and pharmacokinetics of naltrexone implant | Federal Flow Through | Research Foundation of Mental Hygiene | 01-Mar-21 | 31-May-25 | 221,637.00 |
| Bies, Dr. Robert R. | The Indiana University-Ohio State University Maternal and Pediatric Precision in Therapeutics Data, Model, Knowledge, and Research Coordination Center (IU-OSU MPRINT DMKRCC) | Federal Flow Through | Trustees of Indiana University | 10-Sep-21 | 31-Jul-26 | 1,865,877.00 |
| Bies, Dr. Robert R. | Microbicide R&D to Advance HIV Prevention Technologies through Responsive Innovation and eXcellence, MATRIX | Federal Flow Through | Magee-Womens Research Institute and Foundation | 01-Dec-21 | 31-Dec-26 | 1,413,208.00 |
| Bies, Dr. Robert R | Reproductive Tract PBPK & Exposure Modeling | Nonfederal | Magee-Womens Research Institute and Foundation | 07-Nov-22 | 30-Sep-25 | 168,979.00 |
| Chen, Dr. Liang | SBIR: Development of a Rapid Phenotypic Pyrazinamide Susceptibility Testing for Mycobacterium tuberculosis Using Well-Standardized Protocol | Federal Flow Through | PZA Innovation Limited Liability Company | 02-Jan-24 | 31-Dec-25 | 350,000.00 |
| Cieri-Hutcherson, Dr. Nicole E | Motivators and barriers to precepting introductory and advanced pharmacy practice experiential rotations | Nonfederal | American College of Clinical Pharmacy | 15-Jun-24 | 14-Jun-25 | 1,000.00 |
| Daly, Dr. Christopher | Addressing Vaccine Confidence and Uptake in Urban New York Community Pharmacies | Nonfederal | Merck Sharp and Dohme Limited Liability Corporation | 21-Feb-25 | 30-Sep-26 | 83,797.34 |
| Das, Dr. Bhaskar | Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma | Federal Flow Through | University of California at Irvine | 01-Jun-24 | 31-May-26 | 251,290.00 |
| Das, Dr. Bhaskar | Blocking Pathologic Crosstalk Between Podocytes and Endothelial Cells in FSGS | Federal | US Army Medical Research Acquisition Activity | 01-Dec-24 | 30-Apr-28 | 1,232,000.00 |
| Das, Dr. Bhaskar | KLF2 is a novel endoprotective target for DKD | Federal Flow Through | Icahn School of Medicine at Mount Sinai | 20-Sep-24 | 31-May-29 | 1,001,000.00 |
| Das, Dr. Bhaskar | Hippo-YAP in podocyte health and disease | Federal Flow Through | Icahn School of Medicine at Mount Sinai | 01-Aug-24 | 31-May-29 | 377,958.00 |
| Das, Dr. Bhaskar | Podocyte-specific Rap1 agonism for treatment of glomerular disease | Federal Flow Through | Icahn School of Medicine at Mount Sinai | 01-Jul-24 | 28-Feb-27 | 270,736.94 |
| Das, Dr. Sasmita | Assessment of a recently developed boron-based HIF inhibitor as a prospective therapy for renal cell carcinoma (RCC) | Federal Flow Through | Curators of the University of Missouri | 07-Aug-24 | 31-Jul-26 | 80,000.00 |
| Gallo, Dr. James | Cell State Network-Directed Therapy | Federal Flow Through | Clemson University | 20-Sep-24 | 31-Aug-29 | 1,212,836.00 |
| Gallo, Dr. James | Targeting trained immunity in transplantation - Core B | Federal Flow Through | Icahn School of Medicine at Mount Sinai | 01-Jun-23 | 31-Mar-28 | 230,216.00 |
| Jacobs, Dr. David Matthew | Integrative Informatics Approach to Predict Readmissions and Improve Outcomes in COPD | Federal | National Heart Lung and Blood Institute | 01-Apr-21 | 31-Mar-26 | 962,055.00 |
| Jusko, Dr. William J. | Training Program in Pharmacokinetics and Pharmacodynamics | Nonfederal | GlaxoSmithKline | 03-Feb-21 | 20-Aug-25 | 512,400.00 |
| Lao, Dr. Yeh-Hsing Sima | Nanoformulated CRISPR Ribonucleoproteins for Ultrasound-Facilitated Brain Gene Editing | Federal | National Inst of Neurological Disorders & Stroke | 01-Jul-23 | 30-Jun-25 | 442,000.00 |
| Lazarus, Dr. Philip | Gene-tobacco carcinogen interactions and lung cancer risk - a novel approach for precision cancer prevention | Federal | National Cancer Institute | 01-Dec-24 | 30-Nov-27 | 1,947,390.00 |
| Ma, Dr. Qing | Doravirine Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals | Nonfederal | Merck Sharp and Dohme Limited Liability Corporation | 04-Jun-19 | 30-May-25 | 242,646.38 |
| Ma, Dr. Qing | Bictegravir in the Elderly Living with HIV: Impact of Polypharmacy and Multimorbidity | Nonfederal | Gilead Sciences Incorporated | 01-Oct-19 | 31-Dec-25 | 155,175.00 |
| Ma, Dr. Qing | Aging, Polypharmacy and Neurotoxicity in Adults Living with HIV | Federal | National Institute on Aging | 01-May-20 | 28-Feb-26 | 4,006,139.00 |
| Ma, Dr. Qing | An Open-label Study Evaluating Pharmacokinetics, Efficacy, Safety, and Tolerability of CABENUVA IM Administered Monthly and Every 2 months in Virologically Suppressed HIV-Infected Adults having Severe Renal Impairment With or Without Hemodi | Nonfederal | Alleghany Singer Research Institute | 28-Feb-24 | 30-Sep-26 | 18,685.00 |
| Mager, Dr. Donald E. | Novel Synthetic Lethality Strategy for TP53 Mutant Colorectal Cancer | Federal Flow Through | Health Research Inc. | 10-Aug-23 | 31-Jul-25 | 63,555.00 |
| Mager, Dr. Donald E. | Optimizing GVHD Prevention with Systems Pharmacology Models | Federal Flow Through | Beckman Research Institute of the City of Hope | 01-Jun-19 | 31-May-25 | 646,324.00 |
| Morse, Dr. Gene | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections [ACTG LOC_ SP CR: PPMD ] | Federal Flow Through | Regents of the University of California Los Angeles | 01-Dec-20 | 30-Nov-25 | 774,564.00 |
| Morse, Dr. Gene | University of Rochester HIV/AIDS Clinical Trial Unit - AWD00003932 | Federal Flow Through | University of Rochester | 01-Dec-20 | 30-Nov-27 | 187,935.00 |
| Morse, Dr. Gene | HIV Clinical Pharmacology & Therapeutics Research Training Program | Federal | Fogarty International Center | 01-Mar-22 | 31-Jan-27 | 1,507,744.94 |
| Morse, Dr. Gene | Clinical Pharmacology Quality Assurance (CPQA) | Federal | National Institute of Allergy & Infectious Disease | 30-May-22 | 29-May-29 | 14,561,135.00 |
| Morse, Dr. Gene | CENTER FOR INTEGRATED GLOBAL BIOMEDICAL SCIENCES | Nonfederal | Abbott Laboratories | 23-Nov-22 | 31-Jul-25 | 174,900.00 |
| Morse, Dr. Gene | Global Infectious Diseases Research Training Program | Federal | Fogarty International Center | 01-Mar-23 | 31-Dec-27 | 1,833,196.00 |
| Prescott, Dr. Gina | Affordable Care Act: Public Health Training Centers Program | Federal Flow Through | D'Youville University | 01-Jun-2023 | 14-Sep-25 | 150,000.00 |
| Qu, Dr. Jun | Robust Mass Spectrometric Protein/Peptide Assays for Type 1 Diabetes Clinical Applications | Federal | Pacific Northwest Laboratory | 12-Mar-24 | 30-Jun-27 | 625,391.72 |
| Qu, Dr. Jun | UB CAT: Assessing an Alzheimer's Peptide Vaccine | Nonfederal | POP Biotechnologies Incorporated | 01-Jul-24 | 30-Jun-25 | 40,034.96 |
| Qu, Dr. Jun | Identifying Chemo-Neoepitopes for the Chemo-Immunotherapy Against Triple-Negative Breast Cancer | Federal Flow Through | Health Research Inc | 01-Jun-24 | 31-May-25 | 15,902.00 |
| Qu, Dr. Jun | Quantitation of CLDN in tissues | Nonfederal | Boehringer Ingelheim Pharmaceutical | 07-Aug-24 | 06-Aug-26 | 300,000.00 |
| Qu, Dr. Jun | Regulation of and Target Recognition by Protein Arginine Methyltransferase 1 (PRMT1) | Federal Flow Through | Utah State University | 01-Sep-24 | 30-Apr-26 | 32,226.00 |
| Qu, Dr. Jun | Membrane protein analysis and MASP tissue mapping | Nonfederal | Boehringer Ingelheim Pharmaceutical | 07-Aug-2024 | 06-Aug-26 | 300,000.00 |
| Qu, Dr. Jun | Role of Type 2 Immune Response in Pancreatic Cancer Tumorgenisis | Federal Flow Through | Health Research Inc | 15-Jul-21 | 30-Jun-25 | 39,175.00 |
| Qu, Dr. Jun | Dissecting the Mechanism of SETDB1 and its K867 Monoubiquitination in Lung Cancer Progression | Federal Flow Through | Health Research Inc. | 05-Aug-22 | 31-Jul-25 | 22,080.00 |
| Qu, Dr. Jun | Mitochondrial Defects in the Retinal Pigment Epithelium and the CFH Risk Allele for Age-related Macular Degeneration | Federal Flow Through | Doheny Eye Institute | 30-Sep-22 | 30-Jun-26 | 254,607.00 |
| Qu, Dr. Jun | Deciphering the Mechanisms Associated with High-risk AMD genotypes for ARMS2/HTRA1 and Complement Factor H | Federal Flow Through | Doheny Eye Institute | 30-Sep-22 | 31-Aug-25 | 191,140.00 |
| Qu, Dr. Jun | Mechanisms underlying extracellular vesicle mediated changes in inflammation, neural circuitry and plasticity following cortical injury in aged monkeys | Federal Flow Through | Trustees of Boston University | 15-Jul-22 | 30-Jun-27 | 283,312.00 |
| Ramanathan, Dr. Murali | Characterization of PK-PD and Model-Informed Drug Development | Nonfederal | Bill and Melinda Gates Foundation | 14-Oct-24 | 31-Oct-25 | 273,304.00 |
| Ramanathan, Dr. Murali | The Metabolomics-Neurofilaments-Neurodegeneration Nexus in Multiple Sclerosis Progression | Federal | US Army Medical Research Acquisition Activity | 01-Jul-20 | 30-Jun-25 | 957,000.00 |
| Shah, Dr. Dhavalkumar | Training program in pharmacokinetics and pharmacodynamics for a visiting scientist from Japan Tobacco, Inc. | Nonfederal | Japan Tobacco Incorporated | 26-Aug-24 | 25-Aug-25 | 80,500.00 |
| Shah, Dr. Dhavalkumar | Localization of Antibody Drugs to Arthritic Joints via Collagen Hybridization | Federal Flow Through | University of Utah | 22-Aug-24 | 31-Jul-27 | 61,326.00 |
| Shah, Dr. Dhavalkumar | Development of organ-specific quantitative systems toxicology models for antibody-drug conjugates | Nonfederal | AstraZeneca Pharmaceuticals LP | 01-Apr-22 | 09-Oct-25 | 465,771.00 |
| Shah, Dr. Dhavalkumar | Polyesters with controlled topologies for probing transcytosis at the gut-blood barrier | Federal Flow Through | University of Alabama | 15-Sep-23 | 30-Jun-27 | 304,032.00 |
| Smith, Dr. Nicholas M | Pharmacokinetics and Pharmacodynamics of Mechanistically Aware Phage Cocktails | Federal | National Institute of Allergy & Infectious Disease | 01-Jul-24 | 31-Jul-29 | 3,647,260.00 |
| Sprowl, Dr. Jason Arthur | Regulation of hepatic uptake transporters by tyrosine kinases | Federal | National Institute of General Medical Sciences | 15-Sep-21 | 31-Aug-26 | 2,321,588.00 |
| Sprowl, Dr. Jason Arthur | Role of MCT6 in mediating cisplatin-induced ototoxicity | Federal | National Inst on Deafness & Other Comm Disorders | 01-Apr-23 | 31-Mar-26 | 432,182.00 |
| Sprowl, Dr. Jason Arthur | CAREER: Tyrosine Phosphorylation and Kinase Activity as a Regulator of Sodium-Glucose Transporters | Federal | National Science Foundation | 01-Mar-24 | 28-Feb-29 | 746,886.00 |
| Straubinger, Dr. Robert M. | Fellowship for Jonathan Perri: Nanoparticle-Based Approaches to Generate Integrated Immune Responses in Immune Deficient Solid Tumors | Nonfederal | American Foundation Pharmaceutical Education | 01-Sep-24 | 31-Aug-25 | 10,000.00 |
| Tornatore, Dr. Kathleen M. | Age and Race Influences on Immunosuppression after Renal Transplant | Federal | National Institute on Aging | 15-Aug-18 | 30-Jun-25 | 3,507,814.00 |
| Tsuji, Dr. Brian T. | Novel Strategies for Antibiotic Combinations to Combat Gram-negative Superbugs | Federal | National Institute of Allergy & Infectious Disease | 20-Dec-19 | 30-Nov-25 | 3,920,362.00 |
| Tsuji, Dr. Brian T. | Exploitation of multiple heteroresistance for effective antibiotic combination therapy | Federal Flow Through | Emory University | 01-Jul-20 | 30-Jun-25 | 405,663.00 |
| Tsuji, Dr. Brian T. | Novel Combination Therapies to Combat Hypermutable Carbapenem-Resistant P. aeruginosa | Federal | National Institute of Allergy & Infectious Disease | 24-May-22 | 30-Apr-27 | 3,850,992.00 |
| Woo, Dr. Sukyung | Targeting ovarian cancer spheroid formation and metabolic adaptation by APJ inhibition | Federal | National Cancer Institute | 01-Dec-21 | 30-Nov-26 | 1,949,214.00 |
| Woo, Dr. Sukyung | Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold | Federal Flow Through | Board of Regents of the University of Oklahoma | 01-Jul-22 | 30-Jun-27 | 408,175.00 |
| Woo, Dr. Sukyung | Route 66 Endometrial Cancer SPORE | Federal Flow Through | Washington University | 23-Aug-23 | 31-Jul-28 | 235,301.00 |
| You, Dr. Young Jae | Singlet Oxygen-cleavable Prodrugs for Treating Non-Muscle Invasive Bladder Cancers | Federal | National Cancer Institute | 13-Jul-22 | 30-Jun-27 | 2,080,525.00 |
| You, Dr. Young Jae | Site Specific Drug Delivery with Light-responsive Conjugates for Photo-biomodulation | Federal | National Institute of General Medical Sciences | 01-Aug-23 | 31-Jul-27 | 1,372,031.00 |
| Zhao, Dr. Yanan | Novel Biamyxins targeting multidrug resistant Gram-negative bacterial infections | Federal | National Institute of Allergy & Infectious Disease | 02-Jul-24 | 30-Jun-29 | 3,898,070.00 |